CP
RARE icon

Castleview Partners’s Ultragenyx Pharmaceutical RARE Stock Holding History

Castleview Partners’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-6
Closed -$277 – 709
2022
Q4 		$277 Buy
+6
New +$236 ﹤0.01% 605

Other funds holding RARE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Castleview Partners's RARE Position: Q1 2023 in Review

Castleview Partners sold out of Ultragenyx Pharmaceutical (RARE) in Q1 2023, closing a stake of 6 shares — an estimated $277 sold.

Castleview Partners first reported a position in RARE in Q4 2022 and held it in 1 quarter. The position peaked at $277 in Q4 2022. 228 funds tracked by Wall St. Rank hold RARE as of Q1 2023.

  • Castleview Partners reported no remaining Ultragenyx Pharmaceutical position as of Q1 2023 after selling out during the quarter.
  • Castleview Partners sold 6 Ultragenyx Pharmaceutical shares in Q1 2023, an estimated $277.
  • Castleview Partners first reported a position in Ultragenyx Pharmaceutical in Q4 2022 and held it in 1 quarter.
  • Castleview Partners's Ultragenyx Pharmaceutical position peaked at $277 in Q4 2022.
  • 228 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2023.

Based on Castleview Partners's 13F filing for Q1 2023, filed 16 May 2023.